tril

Samsung Biologics’ Plant 4 in Songdo, Incheon / Courtesy of Samsung Biologics By Baek Byung-yeul Samsung Biologics has surpassed 3 trillion won ($2.3 billion) in accumulated annual orders with its contract development and manufacturing organization (CDMO) drug manufacturing business thanks to a recent large-scale contract with an Asia-based pharmaceutical company, according to the drugmaker, Tuesday. […]